What is PreciseDx?
PreciseDx operates at the intersection of pathology and data science, serving as the only cancer risk stratification company that provides patient-specific risk information through the analysis of morphology features. By digitizing and analyzing complex morphological data, the company enables healthcare providers to move beyond traditional diagnostic methods, offering a more personalized approach to treatment planning. This technological edge positions PreciseDx as a vital player in the precision medicine landscape, where the demand for actionable, data-driven insights is rapidly increasing among oncologists and health systems alike.
How much funding has PreciseDx raised?
PreciseDx has raised a total of $42.5M across 3 funding rounds:
Series A
$10.8M
Series B
$20.7M
Other Financing Round
$11M
Series A (2022): $10.8M with participation from Mount Sinai Health System, Merck GHI, and Agile Technologies
Series B (2024): $20.7M led by Quest Diagnostics, Eventide Asset Management, and Labcorp
Other Financing Round (2025): $11M supported by Labcorp, GenHenn Capital, Quest Diagnostics Inc, Eventide Asset Management, Merck & Co, and Philip Ventures
Key Investors in PreciseDx
Labcorp
Labcorp is a global laboratory services leader providing vital diagnostic information to healthcare providers, pharmaceutical companies, and patients to facilitate confident medical decision-making.
Quest Diagnostics
Quest Diagnostics is a pioneer in diagnostic testing and cancer diagnostics, leveraging the world's largest database of clinical lab results to improve health outcomes.
Eventide Asset Management
Eventide Asset Management is an investment firm that emphasizes a values-based approach, focusing on healthcare and technology sectors to generate both financial returns and positive social impact.
What's next for PreciseDx?
With the recent completion of its latest financing round, PreciseDx is well-positioned to accelerate the commercialization of its diagnostic suite. The strategic focus will likely shift toward deepening partnerships with major laboratory networks and expanding the clinical validation of its morphology-based risk models. By integrating these insights into standard clinical workflows, the company aims to improve patient outcomes while reducing the variability often associated with traditional cancer staging. Future growth will be driven by the continued adoption of its platform, supported by the robust financial backing of its diverse investor base.
See full PreciseDx company page
